Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00575653 · ClinicalTrials.gov registry record
Safety Study of GBS Following Menactra Meningococcal Vaccination
A clinical trial of Guillain-Barre Syndrome, sponsored by Harvard Pilgrim Health Care.
- Completed
- Registry status
- 6,000,000
- Enrollment target
- 6
- Study locations
NCT00575653 is a study of Guillain-Barre Syndrome that has completed, run by Harvard Pilgrim Health Care. The registered enrollment target is 6,000,000 participants. The trial reports 6 study locations across 4 states.
The verdict
NCT00575653, a study of Guillain-Barre Syndrome, has completed, sponsored by Harvard Pilgrim Health Care.
- COMPLETED
- Registry status
- 6,000,000 participants
- Enrollment target
- 6
- Study locations
Study Summary
We are conducting a large, record-based study to assess the risk of Guillain-Barré Syndrome (GBS), a serious demyelinating disease, following immunization with the tetravalent meningococcal conjugate vaccine (Menactra) that is currently recommended for all adolescents. The study was requested by CDC and FDA because of an unexpected number of case reports to the CDC's Vaccine Adverse Event Reporting System (VAERS). The study protocol was designed by the investigators, with input from FDA, CDC, and the vaccine's manufacturer, Sanofi-Pasteur. An external advisory board that includes CDC representation, provides input regarding important decisions. The manufacturer is not participating in the conduct of the study and has no control over the analysis or dissemination of results. The study is derived from five large US health plans with a total membership of approximately 50 million over the study time period. America's Health Insurance Plans (AHIP) serves as liaison between the health plans and the Coordinating Center at the Department of Ambulatory Care and Prevention of Harvard Medical School and Harvard Pilgrim Health Care, and is the contracting organization with the health plans.
Conditions Studied
Study Locations (6)
Massachusetts
- Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care - Boston
- i3 Drug Safety - Waltham
Pennsylvania
- Aetna, Inc. - Blue Bell
- Highmark Blue Cross Blue Shield - Pittsburgh
Delaware
- HealthCore, Inc. - Wilmington
Hawaii
- Kaiser Permanente Center for Health Research Hawaii - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000,000 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00575653
The ClinicalTrials.gov registry entry for NCT00575653 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6,000,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harvard Pilgrim Health Care, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Guillain-Barre Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT00575653 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Pennsylvania, Delaware.
Frequently Asked Questions
What is clinical trial NCT00575653 about?
NCT00575653 is a clinical study titled "Safety Study of GBS Following Menactra Meningococcal Vaccination". We are conducting a large, record-based study to assess the risk of Guillain-Barré Syndrome (GBS), a serious demyelinating disease, following immunization with the tetravalent meningococcal conjugate vaccine (Menactra) that is currently recommended for all adolescents. The study was requested by CDC...
What is the current status of trial NCT00575653?
This trial is currently completed. The enrollment target is 6,000,000 participants. The study started on 2005-03. Estimated completion is 2010-12-31.
What conditions does trial NCT00575653 study?
This clinical trial studies the following conditions: Guillain-Barre Syndrome.
Who is sponsoring clinical trial NCT00575653?
This trial is sponsored by Harvard Pilgrim Health Care, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00575653 being conducted?
This trial has 6 study locations across Delaware, Hawaii, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Guillain-Barre Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.